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ABSTRACT 
Two-stage designs are considered for clinical trials involving two 
treatments with dichotomous responses. The first is the information-
gathering stage; the treatment indicated to be the better from first-stage 
and prior data is used exclusively in the second stage. The objective is 
to maximize the expected number of successes in the entire trial. The 
length of the first stage is allowed to be arbitrary and fixed in advance, 
or to be optimized as a function of prior information and the patient 
horizon. In both cases the numbers of patients allocated to the two 
treatments in the first stage are to be optimized. Two forms of prior 
information are considered: the success probabilities are both known but 
which treatment has the larger of the two is not known, and one success 
probability is known while the other has an arbitrary distribution. 
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1. INTRODUCTION 
Patients in a clinical trial are assigned treatments from among those 
under consideration. The assignments are usually made randomly (cf. Simon 
1977): each patient is assigned a treatment according to some predetermined 
probability distribubion. But there is a large ~iterature (Bather 1981, 
Berry 1972, 1978, Feldman 1962, Petkau 1978, Simon, Weiss, and Hoel 1975, 
Zelen 1969) in which assignments are made sequentially, depending on 
accumulating information about the various treatments. 
According to Bailar (1976) and Simon (1977), sequential designs are 
not used in practice, and for a variety of reasons. While the overriding 
reason seems to be philosophical, there are mundane problems which result 
froni the dependence of sequential procedures on "current information". 
Most sequential designs allocate according to the results of all previous 
allocations and so require instantaneous responses. There are few actual 
trials in which the possibility of making continual modifications of the 
design is present--for example, no multicenter trials have this ability. 
More typically, trials proceed in stages, with a committee of clinicians 
and biometricians deciding on changes in protocol at periodic intervals. 
Even if the possibility of continual modification existed, the logistical 
problems involved might be insurmountable. 
Much of the relevant literature (Anscombe 1963, Armitage 1975, Chernoff 
and Petkau 1981, Colton 1963, Cornfield, Halperin, and Greenhouse 1969, 
Day 1969) concerns two-stage trials, the first stage of which involves 
experimentation with two treatments, and normally distributed responses. 
More recently, Langenberg and Srinivasan (1981) consider two procedures 
for splitting the first stage to allow for response delays. These papers 
all assume gain to be relative, depending only on the difference in the 
mean treatment response. 
In this paper we consider two-stage trials in which responses are 
dichotomous. Responses from the first stage are assumed to be available in 
determining the allocation for the second stage. This assumption is only 
approximately correct in trials where stages follow each other immediately, 
for not all of the recent patients will have responded. In such trials, 
modifications of the procedures considered here will be evident, but 
optimality may be lost. While response time should affect the number and 
lengths of stages in an actual trial, these will be assumed independent for 
convenience. In particular, we assume that the total number of patients in 
the trial, N, is fixed. We consider two circumstances for the length n 
of the first stage: first, n is fixed, and seeond, n is optimized. 
The objective of the trial is to maximize the expected proportion of 
successes in the entire trial; the worth of a procedure is the expected 
success proportion when following that procedure. A procedure with maximal 
worth is said to be optimal. This focus on number of successes in the trial 
rather than on the difference between the effectiveness in the two treatments 
seems more natural--in addition, ideas generalize to more than two 
treatments. 
Observations on the two treatments, labeled 1 and 2, can be 
represented by Bernoulli processes with success probabilities and 
The parameters and are not precisely known and information 
concerning the treatments can be formulated in terms of a joint prior 
distribution measure, F, on and We assume that observations 
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on each treatment are exchangeable so that at any stage the number of 
successes and failures on the two treatments in the previous stages, denoted 
by (s1 ,f1 ;s2,f2), are sufficient statistics for (p1 ,p2). According to 
Bayes's theorem, the posterior measure of (p1 ,p2) is proportional to 
A procedure for allocating treatments in the trial must specify, at 
each stage, the number of patients assigned to each treatment. Since the 
patients are assumed to be exchangeable any allocation of these numbers 
within the stage is acceptable, however, to lessen the possibility of bias 
the allocations should be randomized within each stage. Following an 
optimal procedure, the treatment with the larger probability of success, 
given by the maximum of the current means of the p., would be used 
. ]. 
exclusively in the second and final stage. Therefore, a procedure can be 
specified by n1 and n2 , the numbers of observations on the two treatments 
in the first stage. Whether or not n = n1+n2 is to be optimized, the 
corresponding worth is given by W(n1 ,n2 ;N;F), or more simply, 
(1.1) 
where the initial distribution F is given throughout and X. ]. is the 
number of successes in the n. observations on treatment i in the first 
]. 
stage. The joint distribution of x1 and x2 is given by 
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for i = o, ... ,n, j = o, ... ,n. 
E~ample 1.1. Assume a "flat" or uniform joint density in the unit square 
Suppose N = 10 and n = 5 (which may 
not be an optimal first-stage length). For treatment allocation (n1 ,n2) 
we have 
and 
The relevant calculations yield: W(5,0) = .55357, W(4,l) = .55833, and 
W(3,2) = .56250. Since and p2 are exchangeable in this example, 
allocation (3,2) and (2,3) are both optimal (when n = 5).a 
The worth of any allocation is a convex combination of the probabilities 
of success in the first and second stages. It is evident from (1.1) that 
the second probability is not smaller than the first. Therefore, if the 
second stage is lengthened while the first stage is unchanged the worth is 
not decreased. This means that, for all n1 , n2 , N, F, and M ~ 0, 
and in turn implies the following theorem. 
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THEOREM 1.1. Whether n = n1+n2 is fixed or optimized, for all F and 
M ~ O, 
max W(n1 ,n2;N;F) < 
nl,n2 
max W(n1 ,n2;N+M;F). 
nl,n2 
In each of the next two sections we consider 'two kinds of trials: the 
first and second stages are of predetermined lengths and the length of the 
first stage is to be optimized -- both with N fixed. In Section 2, F has 
a two-point distribution of a certain type. In Section 3, Pz is known 
(but arbitrary) and p1 has an arbitrary distribution. 
- 5 -
2. DEPENDENT TREATMENTS 
Feldman (1962) considers a special kind of prior distribution, F, 
under which and are dependent, one which assigns all its mass 
to two points: (a,a) and (6,a). He assumes that the N patients are 
treated sequentially with the results of all previous patients available 
before treating the present patient. He shows that a myopic procedure, 
one which assigns the treatment with the larger current (expected) 
probability of success to the present patient, is optimal. Kelley (1974) 
finds necessary and sufficient conditions for optimality of myopic 
procedures when the distribution is concentrated on two points. 
In the current setting, a myopic allocation assigns all patients in 
the first stage to the treatment with the larger initial probability of 
success. We will show, by example, that myopic allocations are not always 
optimal whether or not the length of the first stage is optimized. However, 
as the trial length approaches infinity, the asymptotic worth of a myopic 
allocation will, in both cases, approach the asymptotic worth of an 
optimal allocation. 
Using a slightly ambiguous notation, we let F denote the initial 
probability that (pl' p 2) = (a, a) . Also, let F(sl's2) denote the 
probability of (a, a) given s. successes in n. observations on 
1 1 
treatment i. From Bayes's theorem 
(2 .1) -1. . (1-F)(a)i-j(l-6)nl-i-(n2-j) F (1 J) = 1 + - - - . 
' F a 1-a 
From (1.1) and (2.1), the worth of an allocation (n1 ,n2) is given by 
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(2.2) 
• max{F(i,j)a + (1-F(i,j))a, (1-F(i,j))a + F(i,j)a} 
+ (N-n -n ) (a-a) ~1 ~2 (~1)(~2) 
1 2 i=O j=O i J 
• max Fai(l-a)nl-iaj(l-a)n2-j, (l-F)aj(l-a)n2-jai(l-8)nl-i}. 
2.1. Fixed Length First Stage 
When n is fixed an allocation is found by maximizing (2.2) over 
(n1 , n2) for which n1 + n2 = n. Optimal allocations and their worths for 
various a, 8, n, N, and F = 1/2 are shown in Tables 2.1 and 2.2. These 
were calculated by enumeration of (2.2). 
[Tables 2.1 and 2.2 about here] 
The following theorems rely on the special nature of F and clarify 
the allocation problem somewhat. 
THEOREM 2.1. For n fixed and two-point distributions on {(a,8),(8,a)} 
with O 2. 8 2. a< 1 and O 2. F 2- 1, 
(2. 3) 
for all O < n. < n, n1+n2 = n. - 1 -
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• 
Proof. Immediate from considerations of symmetry, or from (2.2).a 
When a= 1-a, (2.1) becomes 
(2. 4) 
so that a success on treatment 1 has the same effect on the distribution 
of (p1,p2) as a failure on treatment 2. Furthermore, if a= 1-a and 
F = 1/2 then every allocation for the first stage is optimal: 
THEOREM 2.2. For n fixed and two-point distributions on {(a,l-a),(1-a,a)} 
with 1/2 2_ a 2_ 1, 
W(n1 ,n2;N;l/2) = W(n,O;N;l/2), 
for all O 2_ ni 2. n such that n1+n2 = n. 
Proof. It follows from (2.2) that 
(2.5) 
+ 2a2-l y ? (~1)(~2) i=O J=O 1 J 
and it is sufficient to show that 
(2. 6) n1 nz (n )(n) . i+n -j n -i+j j+n -i i+n -j E _E •1 .2 max{Fa 2 (1-~) 1 , (1-F)a 1 (1-a) 2 
i=O J=O 1 J 
= E • max{Fa (1-a) , (1-F)a (1-a) } n (n ) i n-i n-i i 
i=O 1. 
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for all (n1,n2) such that n1+n2 = n. Actually, (2.6) is needed only 
for F = 1/2 but the more general result will be used in the proof of 
Theorem 2.3. 
The left side of (2.6) equals 
The result follows since 
The next theorem says that myopic procedures are optimal for some 
rather special two-point distributions. So in these cases it is optimal 
to allocate all n patients in the first stage to the same treatment. 
THEOREM 2.3. For n fixed and two-point distributions on {(a,B),(B,a)}, 
myopic allocations are optimal in each of three cases: a= 1-B .::_ 1/2, 
a= 1, and B = 0. 
Proof. For a= 1-B .::_ 1/2, it follows from (2.5) and (2.6) that the 
expected number of successes from the second stage is independent of the 
treatment allocation in the first stage. Therefore, a myopic allocation 
is optimal. 
When a= 1, 
= B + (1-B)[n1F + n2 (1-F)]/N + (1-B)max{FBn
2
, (1-F)Bn1}/2 
+ :r (~1)(1-F)fhl-ll,nl-J 
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which is maximized by n1 = 0 or n according as F ~ 1/2 or F ~ 1/2. 
The case a= 0 follows by a similar argument.a 
Although the worth of a myopic allocation usually compares favorably 
with the worth of an optimal allocation for (a,e) and F not considered 
in the above theorem, as the next example suggests, a myopic allocation is 
not always optimal. 
Example 2.1. Suppose a= .8 and e = .4. Then 
W(6,0) = W(0,6) = .672192, 
which is somewhat less than 
W(S,1) = W(l,5) = .672704. 
The only optimal allocations are (5,1) and (1,5).a 
While not necessarily optimal, myopic allocations are asymptotically 
optimal, as the subsequent development will show. First, we find an upper 
bound for the worth of an optimal allocation and then show that as the 
trial length becomes large both the worth of the optimal and myopic 
allocations approach this upper bound. 
THEOREM 2.4. For n fixed and two-point distributions on {(a,e),.(e,a)} 
with O < e ~a< 1 and O < F ~ 1, 
(2.7) 
for all O 2. ni ~ n with n1+n2 = n. 
Proof. The expected number of successes from the first stage is 
n1 (Fa+(l-F)e) + n2 (Fe+(l-F)a). The maximum expected number of successes 
from the second stage is na which would result if and P2 were 
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to become known after the first stage -- if F(Xl'X2) = 0 or 1 with 
probability one.a 
Remark. Inequality (2.7) is strict if O < F < 1 and either a> O or 
a < 1. 
The next result is a special case of a well-known phenomenon: 
posterior distributions converge strongly. It is a straightforward 
consequence of the strong law of large numbers. 
LEMMA 2.1. For the two-point distributions on {(a,S),(6,a)} with 
0 < 6 <a< 1 and O < F < 1, 
lim P[F(X1 ,x2)-+ 0 or l.lF] = 1. 
n+oo 
THEOREM 2.5. For two-point distributions on {(a,S),(6,a)}, assume 
0 ~ 6 <a~ 1 and O < F < 1. If n.-+ 00 as n-+ 00 , i = 1, 2, and 
l. 
n1 = o(n) if F < 1/2 and n2 = o(n) if F > 1/2, then 
lim W(n1 ,n2) =[a+ max{Fa+(l-F)6, (l-F)a+F6}]/2. n-+00 
Proof. Under the conditions of the theorem, the maximal expected number 
of successes from the second stage will approach a according to Lemma 
2.1. Choosing n1 = o(n) -if F < 1/2 or n2 = o(n) if F > 1/2 
assures that the expected proportion of successes from the first stage 
equals max{Fa+(l-F)6, (l-F)a+F6} in the limit.a 
While this shows that myopic allocations are asymptotically optimal, 
it makes it clear that many other allocations are also asymptotically 
optimal. 
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2.2. Optimal Length of First Stage 
The restriction that n is fixed in advance is now removed. An 
optimal allocation can be found by maximizing (2.2) over (n1 ,n2) such 
that O 2_ n1 + n2 2_ N. Tables 2.3 and 2.4 give optimal allocations and 
worths for the same combinations of a, a, N and F as considered in 
Tables 2.1 and 2.2, respectively. 
[Tables 2.3 and 2.4 about here] 
The symmetry conditions described in Theorems 2.1 and 2.2 still 
hold. In particular, for a= 1-a ~ 1/2 and F = 1/2 an optimal 
allocation of the form (n,O) can always be found. 
Example 2.2. Let a= 1-a ~ 1/2 and F = 1/2. For n odd, 
(2.8) NW(n,O) [ 
n N-n (n-l) 12 (n) n-i i] 
= N (1-a) + (Za-1) 2 + - 2- i;O i a (1-a) 
N-n n (n) i n-i + (2a-1)-2- r . i a (1-a) i=(n+l)/2 
N 
=-+ 2 (2 -l) N-n [r (n+l n+l) _ 1 (n+l n+l)] a 2 a 2 ' 2 1-a 2 ' 2 ' 
where r8 (p,q) is the incomplete beta function, 
Since 
8 
= [r(p+q)/(r(p)r(q))l J tp-l(l-t)q-ldt. 
0 
b 
= J [ln(t) + ln(l-t)]tx(l-t)xdt 
a 
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for x > 1 and O <a< b ~ 1, the value of n (considered temporarily 
to be real rather than integral) which maximizes (2.8) satisfies the 
equation 
where the random variables T1 and T2 have densities 
for t 1 E (1-a,a) and t 2 E (0,1), and O otherwise. It follows that 
the optimal odd first stage size is decreasing in a for a ~ 1/2 .• 
The above argument can be modified to show that the optimal even 
first stage size is also decreasing in a for a~ 1/2.a 
Tables 2.3 and 2.4 support the notion that the optimal size for the 
first stage is again decreasing in a for a > 1/2 and a .?:. B. Also, 
the maximal worth is increasing in a but not necessarily increasing in 
B. The worth of an optimal allocation for the various values of a, B, 
and F can be compared to a, an upper bound which is attained in the 
limit (as N + 00) by any sequence of allocations where the corresponding 
first stage sizes, nN' satisfy the conditions nN + 00 and °N = o(N) 
as N + 00 • This follows by generalizing the proof of Theorem 2.5. 
A myopic allocation can be shown optimal for the three cases of 
Theorem 2.3 by an evident modification of the proof of that theorem. 
The tables suggest that myopic allocations compare favorably with optimal 
allocations. However, the loss from using a myopic allocation is not as 
great when the first stage has a moderate length (cf. Section 2.1). This 
is because the optimal length of the first stage is typically quite small. 
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3. ONE TREATMENT KNOWN 
Assume that one of the treatments, say treatment 2, has a known 
probability, A, of success. This is applicable when treatment 2 is a 
standard treatment about which much is known. 
When patients are treated individually and the results of all 
previously treated patients are known before treating the current patient, 
Bradt, Karlin, and Johnson (1956) show that optimal procedures are 
partially characterized by the stay-on-a-winner rule: if the current 
treatment results in a success then it is optimal to use that treatment 
on the.next patient as well. Berry and Fristedt (1979) consider discounting 
future patients; the value of the mth patient is b , 
m 
where b +l < b. m - m 
They give necessary and sufficient conditions on the sequence b1 ,b2,b3, ••• 
for optimal procedures to be characterized by the stay-on-a-winner rule 
for all F. However, explicit solutions are not possible for the fully 
sequential problem for any interesting discount sequences (e.g., neither 
finite horizon nor geometric) unless F is very special. In general, a 
backward induction is necessary. 
Again, when there are two stages, a procedure can be specified by 
(n1 ,n2), the numbers of observations on the two treatments in the first 
stage. 
For the purposes of this section, F can be regarded as a pair 
(F1 ,A) where F1 is the prior distribution of p1 and A is the known 
value of Since Pz is known a priori, no amount of experimentation 
on treatment 2 changes F. However, observations on treatment 1 provide 
worthwhile information: the expected proportion of successes in the 
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second stage increases if additional observations are allocated to 
treatment 1 in the first stage. In fact, if n is fixed, the allocation 
(n,O) will be seen to be optimal whenever Ep1 2:_ A. And when n is 
optimized, we will show that it is always optimal to allocate all n 
patients to treatment 1. 
3.1. Fixed Length First Stage 
In this section, n = n1+n2 is fixed in advance. As more generally, 
an optimal allocation can be found by maximizing (1.1). 
# 
The following example shows the interplay between the current 
probability of success and the information to be gained for use in 
obtaining future successes. 
Example 3.1. Suppose n is fixed 2:_ 1, p1 has a two-point distribution 
on {0,1} with F1 ({1}) = p*, and A is arbitrary. Then 
if 
if 
Comparing these expressions, all optimal allocations are seen to satisfy 
the following relations, where y = A(l+n(l-A)): 
For * > A, = p nl n, 
For p* = A, n1 .::_ 1, 
For p* * A and p* < y, nl = o, 
For * * A and * 0 1, p p = Y, nl = or 
For y < * < A, 1. p nl = 
- 15 -
Because the distribution of in this example is so very special, 
complete information concerning treatment 1 can be obtained with but one 
observation. Therefore, if it is optimal to use it more than once in the 
first stage its probability of success must be at least that of treatment 
2, that is, p* ~ A; and if p* > A then treatment 1 must be used 
exclusively in the first stage since its probability of success is greater. 
Furthermore, the information gained from an observation on treatment 1 
means that using it may be wise even though p* is quite small, depending 
on n. For example, when A= 1/2, if 1/(n+2) < p* < 1/2 then it is 
optimal to use treatment 1 once in the first stage. 
The loss in worth from fixing n is apparent here -- in fact, it 
follows from Theorem 3.4 that an optimal length of the first stage is 1, 
uniquely optimal provided p* > A/ (A + N(l-A) ) .•. a 
The following theorem gives an analogue of the stay-on-a-winner rule, 
though it is much weaker than the fully sequential version. Its proof is 
straightforward and is omitted. 
THEOREM 3.1. Assume n is fixed. If an optimal allocation assigns at 
least one patient to treatment 1 in the first stage and every observation 
on treatment 1 results in success then it is optimal to assign all patients 
in the second to treatment 1. 
Obviously, Theorem 3.1 does not hold with treatment 2 in place of 
treatment 1. For, the use of treatment 2 in the second stage is independent 
of its performance in the first stage. 
A phenomenon seen in Example 3.1 holds more generally: 
THEOREM 3.2. For n fixed, if E(p1 1F1) ~ A then (n,O) is an optimal 
allocation, and (n,O) is the uniquely optimal allocation provided 
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Proof. Since Ep1 ~ A, for any allocation (n1 ,n2) the expected success 
proportion in the first stage, 
is nondecreasing in n1 • Therefore, to prove that (n,O) is an optimal 
allocation, it is sufficient to show that the expected proportion of 
successes from the second stage is nonincreasing in n1 • Letting Z 
denote the first observation on treatment 1, 
(3.1) 
with strict inequality provided Ep1 > A and F1 is not a one-point 
distribution. This gives the desired result for n = 1. And since (3.1) 
holds for all F1 , the expected proportion of successes in the second 
stage in nonincreasing for n1 E {0,1, .•• ,n}.a 
The next theorem says that if the trial size is increased, the number 
of patients assigned to treatment 1 in the first stage should not decrease. 
Its proof is not instructive and is omitted. 
THEOREM 3.3. For n fixed, let (n1 ,n2) be an optimal allocation. 
If the number of patients in the second stage is increased then there 
exists an optimal allocation, for the larger trial with 
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(and, therefore, 
Remark. Example 3.1 provides many instances in which ni = n1 • 
Tables 3.1 and 3.2 specify optimal allocations when F1 is a beta 
distribution: 
(3.2) a-1 b-1 dF1 (x) « x (1-x) dx. 
For the grid of A-values chosen for these tables, as A is increased, the 
proportion of patients assigned to treatment 2 does not decrease. But as 
the following example shows, the issue is rather complicated. 
[Tables 3.1 and 3.2 about here] 
Example 3.2. Suppose pl has a uniform density on (0,1), 0 < E < 1/3, 
and n = 2. If A= 1/2 - E then (cf. Theorem 3.2) 
N[W(2,0)-W(l,1)] = (¾ - j )€ , 
which is positive for E > 0 and N > 8. So for N > 8, n1 = 1 is 
optimal (but not uniquely) for A= 1/2 but not op,t!imal for A= 1/2 + E.a 
A clear message from Tables 3.1 and 3.2 is that one treatment or the 
other tends to dominate the first stage (as well as the second -- but 
different treatments may dominate in different stages, depending on the 
results of the first). For example, the least extreme allocation on Table 
3.2 is (12,38). This suggests that n = 50 is too large when N = 100, 
and this suggestion leads to .the next topic. 
3.2. Optimal Length First Stage 
When the length of the first stage is given, Theorem 3.2 applies to 
show that an optimal allocation assigns all patients in the first stage to 
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treatment 1 provided Ep1 ~ X. This result can be easily extended to the 
case in which n is to be optimized. The next theorem has great intuitive 
appeal since the first stage is the information-gathering stage and there 
is nothing to learn about treatment 2 when p2 is known. 
THEOREM 3.4. For all N ~ 1, there exists an n, 0 < n < N, such that 
(n,O) is an optimal first stage allocation. 
Proof. Suppose (n1,n2) is optimal. Then (n1 ,0) is also optimal since 
(3.3) NW(n1 ,0;N;F) = n1Ep1 + (N-n1 )E[max{E(p1 1(x1 ,n1-x1 ;F1)),X}jF1] 
~ n1Ep1 + n2x + (N-n1-n2)E(max{E(p1 1(x1 ,n1-x1 ;F)),X}IF1) 
Two particular situations where the treatment that is optimal for the 
second stage can be determined without computing the posterior probability 
of success for treatment 1, given the results of the first stage, are 
presented next. The first theorem is a variant of the stay-on-a-winner 
rule (cf. Theorem 3.1) and gives a switch-on-a-loser rule. 
THEOREM 3.5. Let N > 2. Assume that a first-stage allocation of the 
form (n,O) with n > 0 is uniquely optimal. Then, treatment 1 is optimal 
for the second stage if all successes are obtained in the first stage and 
treatment 2 is optimal if all failures are obtained. 
Proof. If all successes are obtained in the first stage and treatment 1 
is not optimal for the second stage then 
(3.4) 
In view of (3.3) and (3.4), 
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W(n,O) = [n•Ep1 + (N-n)>d/N 
< X = W(O,O), 
which contradicts the optimality of the allocation (n,O). 
The other result follows by a similar argument.a 
Example 3.3. Suppose p1 has a uniform density on (0,1): beta with 
a.=· b =· 1 (cf. Table 3.3 and 3.4). From calculations similar to those 
in Example 1.1 and using[•] to denote the integer part, it follows that 
n N-n n { i+l } 
N W(n,O) = 2 + n+l i;O max n+2 ' X 
; n + N-n ([X(n;2)-1] 
2 n+l i=O 
+ ~ i+l) 
i=[X(n+2) n+Z 
N N-n 2 
= 2 + 2(n+l) (X (n+2) - X) • 
Differentiation gives 
n * = { (N + 1)( A - l - 1)} l/ 2 - 2 
as an approximation to the optimal first stage size.a 
In the above example, * n is nondecreasing in N. The next theorem 
says that the optimal first stage size in nondecreasing in N. It is a 
reasonably straightforward consequence of Theorem 3.4. 
THEOREM 3.6: Suppose that N < N'. If (n1 ,0) is an optimal allocation 
for a trial of size N, then there exists an ni ~ n1 such that (ni,0) 
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is an optimal allocation for a trial of size N'. 
Remark. Again, Example 3.1 provides many instances in which ni = n1 • 
Tables 3.3 and 3.4 also provide such instances, and cases in which 
as well. 
A generalization of the two-point prior distribution considered in 
Example 3.1 is provided in the following example. 
Example 3.4. Suppose for E > 0 that F1 is a two-point distribution on 
{0,1-E} with F1 ({1-E}) = r, A< 1-E, and O < r < 1. If n observations 
are allocated to treatment 1 in the first stage, then, where 
to denote the number of successes in the first stage, 
and 
n -1 (O,n;Fl)({l-E}) = 1 - [1 + (r/(1-r))E] , 
X 1 continues 
Therefore, since the expected number of successes in the first stage, given 
at least one success, is 1 + (n-1)(1-E), 
NW(n,O) = [1 + (n-1)(1-E) + (N-n)(l-E)]r(l-En) 
· n -1 n + (N-n)max{ (1-e;) (1 - [1 + rE / (1-r)] ) ,. A} [1 - r(l-E ) ] 
n n 
= r(l-e;)[n + (N-n)(l-E )] + (N-n)[l - r(l-E )] 
• max{(l-E)(l - [1 + re;n/(l-r)]-1), A}. 
However, if 
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n -1 (1-E)(l - [1 + rE /(1-r)] ) > A, 
then the worth of the allocation (n,0) is the same as the worth of the 
allocations (N,0) and (0,0). Thus, an optimal allocation and 
corresponding worth can be found by maximizing 
n 
r(l-E)n + (N-n)[r(l-E )(1-E-A) + A]. 
In particular, for A= 1/2, N = 100, r E {.25, .5, .75, .95}, and 
1-E E {.6, .75, .9} an optimal first stage size is 6.a 
Tables 3.3 and 3.4 give optimal first stage sizes for N = 50 and 
100 and various values of A and various beta distributions with parameters 
(a,b) for If Ep = a/(a +b) 1 is held constant, then the size of the 
first stage seems to decrease in a~ b for Ep1 < A and increase for 
[Tables 3.3 and 3.4 about here] 
Throughout this paper the patient horizon· N has been assumed given. 
That optimal allocations and worths may be robust with respect to N can 
be seen b·y comparing Tables 3.3 and 3.4 (and also Tables 2.3 and 2.4). 
Theorem 3.6 says that the number of patients allocated to treatment 1 in 
the first stage for N = 100 cannot be less than when N = 50 (whenever 
both are unique). But even when the optimal allocations are different the 
corresponding worths are not very different: the maximal difference in 
Tables 3.3 and 3.4 is 0.01022 -- for (a ,b) = (1/2,1/2) and :\ = 0.8. 
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Table 2.1. Optimal values of nl,n2 and corresponding worths for F = 1/2, n= 25 and N= 50 
a 
.1 .2 .3 .4 .5 .6 .7 .8 .9 1.0 
13 
0 25 0 25 0 25 0 25 0 25 0 25 0 25 0 25 0 25 0 25 0 
.07338 .14985 .22499 .30000 .37500 .45000 .52500 .60000 .67500 .75000 
.1 25 0 25 0 25 0 23 2 23 2 23 2 25 0 25. 0 25. 0 
.16324 .24058 .32029 .39833 .47459 .54994 .62500 .70000 • 77500 
.2 24 1 22 3 25 0 17 8 24 1 25 0 25 0 25 0 
.26104 .33690 .41745 .49698 .57421 .64989 • 72500 .80000 
.3 19 6 22 3 22 3 24 1 24 1 23 2 25 0 
.36012 .43515 .51610 .59651 .67421 .74994 .82500 
.4 22 3 25 0 22 3 17 8 23 2 25 0 
~ 
.45973 .53462 .61610 .69698 • 77459 .85000 w 
I 
.5 22 3 22 3 25 0 23 2 25 0 
.55973 .63515 .71745 .79833 .87500 
.6 19 6 22 3 25 0 25 0 
.66012 .73690 .82029 .90000 
.7 24 1 25 0 25 0 
• 76104 .84058 .92499 
.8 25 0 25 0 
.86324 .94985 
.9 25 0 
.97338 
Table 2.2. Optimal values of nl,n2 and corresponding worths for F = 1/2, n = 50 and N = 100 
(l 
.1 .2 .3 .4 .5 .6 .7 .8 .. 9 1.0 
f3 
0 50 0 50 0 50 0 50 0 50 0 50 0 50 0 50 0 50 0 50 0 
.07488 .15000 .22500 .30000 .37500 .45000 .52500 .60000 .67500 .75000 
.1 44 6 48 2 48 2 50 0 50 0 48 2 47 3 50 0 50 0 
.16772 .24678 .32434 .39992 .47500 .55000 .62500 .70000 • 77500 
.2 50 0 48 2 45 5 49 1 46 4 50 0 47 3 50 0 
.26478 .34429 .42343 .49977 .57498 .65000 • 72500 .80000 
.3 50 0 47 3 39 11 49 1 46 4 48 2 50 0 
.36363 .44289 .52289 .59967 .67498 .75000 .82500 
N .4 50 0 49 1 39 11 49 1 50 0 50 0 
.i::-, 
.46315 .54224 .62289 .69977 • 77500 .85000 
.5 50 0 47 3 45 5 50 0 50 0 
.56315 .64289 • 72343 .79992 .87500 
.6 50 0 48 2 48 2 50 0 
.66363 .74429 .82434 .90000 
.7 50 0 48 2 50 0 
.76478 .84678 .92500 
.8 44 6 50 0 
.86722 .95000 
.9 50 0 
.97488 
Table 2.3. Optimal values of nl,n2 and corresponding worths for F=l/2 and N= 50 
a 
.1 .2 .3 .4 .5 .6 .7 .8 .9 1.0 
a· 
0 14 0 8 0 7 0 5 0 4 0 3 0 2 0 2 0 1 0 1 0 
.07859 .16926 .27156 .37160 .47281 .57478 .67693 .78093 .88659 .99000 
.1 13 2 13 0 11 0 9 0 8 0 5 1 3 2 3 0 1 0 
.16492 .24911 .34261 .44058 .54154 .64435 .74909 .85494 .98659 
.2 15 1 13 1 11 1 7 3 8 0 7 0 3 2 2 0 
.26237 .34344 .43535 .53373 .63601 .74079 .84909 .98093 
.3 13 3 14 0 11 1 11 0 8 0 5 1 2 0 
.36125 .44093 .53270 .63159 .73601 .84435 .97693 
N> .4 13 3 14 1 11 1 7 3 8 0 3 0 (n 
.46080 . 54017 .63270 .73373 .84154 .97478 
.5 13 3 14 0 11 1 9 0 4 0 
.56080 .64093 .73535 .84058 .97281 
.6 13 3 13 1 11 0 5 0 
.66125 .74344 .84261 • 97160 
.7 15 1 13 0 7 0 
.76237 .84911 • 97156 
.8 13 2 9 0 
.86492 .97320 
.9 14 0 
.97859 
Table 2.4. Optimal values of nl,n2 and corresponding worths for F = 1/2 and N = 100 
a, 
.1 .2 .3 .4 .5 .6 .7 .8 .9 1.0 
'3 
0 20 0 13 0 9 0 7 0 5 0 4 0 3 0 2 0 1 0 1 0 
.08562 .18317 .28264 .38288 .48379 .58505 .68675 .78886 .89105 .99500 
.1 26 2 20 1 16 0 13 0 11 0 8 1 6 0 3 2 1 0 
.16996 .26113 .35917 .46003 .56186 .66456 .76821 .87349 .99105 
.2 30 0 23 1 19 0 12 3 10 2 8 1 6 0 2 0 
.26678 .35539 .45314 .55454 .65774 .76231 .86821 .98886 
.3 30 0 22 3 15 5 14 1 10 2 8 1 3 0 
.36530 .45273 .55057 .65300 • 75774 .86456 .98675 
I 
N 
.4 30 0 24 1 15 5 12 3 11 0 4 0 
°' 
.46478 .55193 .65057 .75454 .86186 .98505 
.5 30 0 22 3 19 0 13 0 5 0 
.56478 .65273 • 75314 .86003 .98379 
.6 30 0 23 1 16 0 7 0 
.66536 .75531 .85917 .98288 
.7 30 0 20 1 9 0 
.76678 • 86113 .98264 
.8 26 2 13 0 
.86996 .98317 
.9 20 0 
.98562 
Table 3.1. Optimal values of nl,n2 and corresponding worths for n = 25 and N = 50 
when P2 = A is known and P1 has a beta distribution (3.2) 
A 
.OS .1 .2 .3 .4 .5 .6 • 7 .8 .9 
(a,b) 
(4,1) 25 0 25 0 25 0 25 0 25 0 25 0 25 0 25 0 25 0 0. 25 
.80000 .80000 .80000 .80009 .80056 .80211 .80601 .81428 .82983 .90000 
(1,½) 25 0 25 0 25 0 25 0 25 0 25 0 25 0 8 17 3 22 0 25 
.66679 .66752 .67102 • 67735 .68680 .69951 • 71584 .74443 .81232 .90000 
(2,1) 25 0 25 0 25 0 25 0 25 0 25 0 25 0 9 16 0 25 0 25 
.66667 .66671 .66748 .67009 .67562 .68519 .70004 . 72824 .80000 .90000 
(½,½) 25 0 25 0 25 0 25 0 25 0 25 0 4 21 2 23 0 25 0 25 
N 
.50173 .50583 • 5181.7 .53464 .55465 .57806 .64083 .71700 .80000 .90000 
"'-J 
(1, 1) 25 0 25 0 25 0 25 0 25 0 25 0 4 21 3 22 0 25 0 25 
.50025 .50171 .50855 .52051 .53775 .56019 .62200 .70050 .80000 .90000 
(2,2) 25 0 25 0 25 0 25 0 25 0 25 0 2 23 0 25 0 25 0 25 
.50000 .50012 .50233 .50920 .52258 .54358 .60600 .70000 .80000 .90000 
(4,4) 25 0 25 0 25 0 25 0 25 0 25 0 0 25 0 25 0 25 0 25 
.50000 .50000 .50019 .50241 .51088 .52982 .60000 .70000 .80000 .90000 
(1,2) 25 0 25 0 25 0 25 0 6 19 2 23 0 25 0 25 0 25 0 25 
.33386 .33673 • 34972 .37118 .41978 .50167 .60000 .70000 .80000 .90000 
(½, 1) 25 0 25 0 25 0 25 0 4 21 2 23 2 23 0 25 0 25 0 25 
.33605 .34250 .36144 .38631 .43706 .51476 .60076 .70000 .80000 .90000 
(1,4) 25 0 25 0 25 0 1 24 0 25 0 25 0 25 0 25 0 25 0 25 
.20115 .20665 .22983 .30133 .40000 .50000 .60000 .70000 .80000 .90000 
Table 3.2. Optimal values of nl,n2 and corresponding worths for n = 50 and N = 100 
when p2 = A is known and P1 has a beta distribution (3.2) 
A 
.05 .1 .2 .3 .4 .5 .6 .7 ' .'8 .9 
(a,b) 
(4,1) 50 0 50 0 50 0 50 0 50 0 50 0 50 0 50 0 50 0 0 50 
.80000 .80000 .80001 .80015 .80076 .80257 .80682 .81549 .83122 .90000 
(1,½) 50 0 50 0 50 0 50 0 50 0 50 0 50 0 12 38 4 46 0 50 
.66687 • 66771 .67142 .67795 - • 68750 .70033 .71673 • 74727 .81683 .90000 
(2 ,1) 50 0 50 0 50 0 50 0 50 0 50 0 50 0 12 38 4 46 0 50 
.66667 .66676 .66771 .67058 .67643 .68632 .70129 .73153 .80419 .90000 
(½,½) 50 0 50 0 50 0 50 0 50 0 50 0 4 46 3 47 3 47 0 50 
N 
.50203 .50632 .51877 .53532 .• 55540 .57879 .64483 • 72134 .80272 .90000 (X) 
(1,1) 50 0 50 0 50 0 50 0 50 0 50 0 7 43 3 47 0 50 0 50 
.50041 .50207 .50924 .52149 .53884 .56127 .62633 .70650 .80000 .90000 
(2,2) 50 0 50 0 50 0 50 0 50 0 50 0 5 45 0 50 0 50 0 50 
.50001 .50028 .50290 .51025 .52399 .54509 .61048 .70000 .80000 .90000 
(4, 4) 50 0 50 0 50 0 50 0 50 0 50 0 3 47 0 50 0 50 0 50 
.50000 .50000 .50039 .50327 .51249 .53171 .60003 .70000 .80000 .90000 
(1,2) 50 0 50 0 50 0 50 0 8 42 4 46 0 50 0 50 0 50 0 50 
.33416 .33741 .35079 • 37242 .42396 .50524 .60000 .70000 .80000 .90000 
(½, 1) 50 0 50 0 50 0 50 0 6 44 4 46 2 48 0 50 0 50 0 50 
.33652 .34319 .36228 • 38716 .44081 .51967 .60610 .70000 .80000 .90000 
(1,4) 50 0 50 0 50 0 4 46 0 50 0 50 0 50 0 50 0 50 0 50 
.20165 .20786 .23122 .30433 .40000 .50000 .60000 .70000 .80000 .90000 
Table 3. 3. Optimal values of nl,n2 and corresponding worths for N = 50 
when p2 = A is known and pl has a beta distribution (3.2) 
A 
.05 .1 .2 .3 .4 .5 .6 .7 .8 .9 
(ab) 
(4,1) 12 0 40 0 32 0 36 0 21 0 16 0 14 0 10 0 8 0 0 0 
.80000 .80000 .80001 .80009 .80059 .80239 .80736 .81920 .84386 .90000 
(1,½) 27 0 22 0 11 0 10 0 7 0 7 0 6 0 5 0 3 0 0 0 
.66679 .66757 .67216 .68150 .69619 .71704 .74553 .78234 .83020 .90000 
(2,1) 42 0 31 0 19 0 15 0 13 0 10 0 8 0 5 0 4 0 0 0 
.66667 .66671 .66753 .67067 .67812 .69231 • 71588 • 75238 .80686 .90000 
(½,½) 18 0 10 0 9 0 6 0 4 0 3 0 4 0 2 0 3 0 0 0 
.50200 .50769 .52684 .55466 • 58984 .63219 .68184 .74000 .80403 .90000 
N 
\0 
i' (1,1) 27 0 21 0 11 0 10 0 7 0 5 0 4 0 3 0 0 0 0 0 
.50025 .50183 .51100 .52909 .55733 .59643 .64720 • 71150 .80000 .90000 
(2, 2) 41 0 30 0 18 0 14 0 10 0 7 0 5 0 0 0 0 0 0 0 
.50000 .50015 .50255 .51129 .53077 • 56515 .61786 .70000 .80000 .90000 
(4,4) 10 0 37 0 29 0 20 0 13 0 9 0 0 0 0 0 0 0 0 0 
.50000 .50000 .50020 .50256 .51294 .54132 .60000 .70000 .80000 .90000 
(1,2) 26 0 20 0 10 0 8 0 6 0 2 0 0 0 0 0 0 0 0 0 
.33387 .33709 .35534 • 38967 .44089 .50933 .60000 .70000 .80000 .90000 
(½,1) 18 0 10 0 8 0 5 0 4 0 3 0 2 0 0 0 0 0 0 0 
.33652 .34555 • 37571 .41901 .47267 .53625 .61128 .70000 .80000 .90000 
(1,4) 24 0 18 0 8 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 
.20115 .20788 .24386 .30743 .40000 .50000 .60000 .70000 .80000 .90000 
Table 3.4. Optimal values of nl,n2 and corresponding worths for N = 100 
when P2 = A is known and P1 has a beta distribution (3,2) 
A 
.05 .1 .2 .3 .4 .5 .6 .7 .8 .9 
(a,b) 
(4,1) 83 0 69 0 47 0 40 0 31 0 26 0 21 0 17 0 12 0 0 0 
.80000 .80000 .80001 .80016 .80088 • 80321 .80918 .82237 .84881 .90000 
(1,½) 45 0 24 0 21 0 14 0 12 0 10 0 8 0 8 0 4 0 0 0 
.66688 .66795 .67334 • 68371 .69970 • 72183 .75128 .78889 .83722 .90000 
(2,1) 64 0 42 0 29 0 22 0 18 0 14 0 11 0 9 0 5 0 0 0 
.66667 .66676 .66791 .67181 .68048 .69618 • 72144 .75932 .81369 .90000 
(½,½) 21 0 18 0 13 0 9 0 7 0 5 0 4 0 5 0 4 0 0 0 
w .50264 .50915 .52984 .55917 .59555 .63916 .68975 .74717 .81425 .90000 
0 
I (1,1) 44 0 24 0 16 0 13 0 9 0 9 0 7 0 3 0 0 0 0 0 
.50043 .50257 .51318 .53314 .56287 .60341 .65500 • 71825 .80000 .90000 
(2,2) 63 0 41 0 28 0 21 0 15 0 11 0 7 0 0 0 0 0 0 0 
.50002 .50029 .50354 .51354 .53561 .57188 .62541 .70000 .80000 .90000 
(4,4) 81 0 66 0 44 0 30 0 23 0 15 0 8 0 0 0 0 b 0 0 
.50000 .50000 .50040 .50378 .51644 • 54720 .60455 .70000 .80000 .90000 
(1,2) 43 0 23 0 15 0 12 0 8 0 4 0 0 0 0 0 0 0 0 0 
.33421 .33849 • 35903 .39587 .44857 .51619 .60000 .70000 .80000 .90000 
(½, 1) 21 0 18 0 9 0 8 0 6 0 5 0 2 0 0 0 0 0 0 0 
.33750 .34775 .38006 .42489 .47920 .54423 .61707 .70000 .80000 .90000 
(1,4) 41 0 21 0 12 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 
.20180 .21033 .24881 .31273 .40000 .50000 .60000 .70000 .80000 .90000 
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